XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash Flows From Operating Activities:    
Net income (loss) $ (7,380,430) $ 16,339,371
Adjustments to reconcile net income (loss) to net cash flows used in operating activities:    
Depreciation and amortization 1,024,238 145,459
Stock-based compensation 776,350 656,378
Change in fair value of warrant derivative liabilities (5,561,789) (21,688,835)
Provision for inventory obsolescence 192,622 361,437
Provision for doubtful accounts receivable (161,768)
Gain on extinguishment of debt (10,000)
Change in fair value of contingent consideration promissory note (486,046)
Increase (decrease) in:    
Accounts receivable – trade 721,540 817,077
Accounts receivable – other (776,216) (265,627)
Inventories 60,960 (1,774,922)
Prepaid expenses 1,848,058 (391,084)
Operating lease right of use assets 201,376 30,332
Other assets (4,799,982) (616,005)
Accounts payable 1,994,602 (307,744)
Accrued expenses (73,127) 79,290
Income taxes payable 9,969 (7,231)
Operating lease obligations (201,375) (41,185)
Contract liabilities 1,678,503 523,516
Net cash used in operating activities (10,932,515) (6,149,773)
Cash Flows from Investing Activities:    
Purchases of property, plant and equipment (1,923,501) (5,452,729)
Additions to intangible assets (54,866) (41,126)
Cash paid for acquisition, net of cash acquired (1,012,552)
Cash paid for acquisition of Medical Billing Company (1,153,627)
Cash paid for asset acquisition of Medical Billing Company (230,000)
Net cash used in investing activities (3,361,994) (6,506,407)
Cash Flows from Financing Activities:    
Repurchase and cancellation of common stock (4,026,523)
Distribution to noncontrolling interest in consolidated subsidiary (15,692)
Net proceeds from sale of common stock in registered direct offerings 13,346,600
Proceeds from issuance of common stock upon exercise of pre-funded warrants 53,224,000
Principal payment on contingent consideration promissory notes (216,822)
Net cash (used in) provided by financing activities (4,259,037) 66,570,600
Net increase (decrease) in cash and cash equivalents (18,553,546) 53,914,420
Cash, cash equivalents, beginning of period 32,007,792 4,361,758
Cash, cash equivalents, end of period 13,454,246 58,276,178
Supplemental disclosures of cash flow information:    
Cash payments for interest 27,059
Cash payments for income taxes 9,969 7,231
Supplemental disclosures of non-cash investing and financing activities:    
Issuance of contingent consideration promissory note for business acquired 855,000 350,000
Assets acquired in business acquisitions 190,631
Liabilities assumed in the business acquisition 387,005 162,552
Goodwill acquired in business acquisitions 2,100,000
Restricted common stock grant 715 450
Restricted common stock forfeitures 65 8
Amounts allocated to initial measurement of warrant derivative liabilities in connection with the warrants and pre-funded warrants $ 51,216,058